AFP and hepatocellular carcinoma: A large multicenter phase II study showed that the sensitivity of PIVKA-II in the diagnosis of early HCC was only 56% (9), and another case-control study demonstrated that PIVKA-II was more efficient than AFP with a sensitivity of 77% (10).